MyPeptideMatchOverview
Ipamorelin is a growth hormone secretagogue—a selective GHSR agonist that stimulates the pituitary to release growth hormone. It is often compared with GHRP-2 and GHRP-6 and is sometimes used in combination with CJC-1295. Ipamorelin is prohibited for compounding in the US. It was on the FDA’s Category 2 list; the nomination was withdrawn in September 2024, and it remains on the 503B Category 2 list. There is no approved pathway for compounding. People seeking legal GH support should consider sermorelin, which is Category 1 (compoundable). Evidence for ipamorelin is moderate—some human studies, but primarily preclinical.
How It Works (Mechanism of Action)
Ipamorelin selectively activates the growth hormone secretagogue receptor (GHSR), leading to GH release with relatively minimal effect on cortisol or prolactin compared with some other secretagogues. It is typically given by subcutaneous injection.
Primary Uses
Marketed for growth hormone release, anti-aging, fat loss, and improved sleep. Evidence is moderate. Not legal for compounding in the US.
